His main research concerns Internal medicine, Gastroenterology, Primary sclerosing cholangitis, Primary biliary cirrhosis and Cholestasis. His studies in Internal medicine integrate themes in fields like Endocrinology and Immunology. His work carried out in the field of Gastroenterology brings together such families of science as Liver transplantation, Incidence, Randomized controlled trial, Placebo and Cohort.
His Primary sclerosing cholangitis research incorporates themes from Genome-wide association study, Prevalence, Epidemiology, Inflammatory bowel disease and Ulcerative colitis. His Primary biliary cirrhosis study combines topics in areas such as Cirrhosis and Confidence interval. He interconnects Cholestasis of pregnancy, Lysophosphatidic acid, Autotaxin, Liver disease and Pharmacology in the investigation of issues within Cholestasis.
His primary scientific interests are in Internal medicine, Gastroenterology, Primary sclerosing cholangitis, Cholestasis and Endocrinology. His Primary biliary cirrhosis, Ursodeoxycholic acid, Bile acid, Cirrhosis and Liver transplantation investigations are all subjects of Internal medicine research. In general Bile acid, his work in Chenodeoxycholic acid is often linked to Tauroursodeoxycholic acid linking many areas of study.
In the subject of general Gastroenterology, his work in Liver disease, Hepatology and Cholestatic pruritus is often linked to In patient, thereby combining diverse domains of study. His Primary sclerosing cholangitis research includes themes of Genome-wide association study, Liver biopsy, Inflammatory bowel disease, Immunology and Ulcerative colitis. His research in Cholestasis intersects with topics in Taurolithocholic acid, Cholestasis of pregnancy, Obeticholic acid and Autotaxin.
Ulrich Beuers focuses on Internal medicine, Gastroenterology, Primary sclerosing cholangitis, Cholestasis and Endocrinology. His research on Internal medicine frequently links to adjacent areas such as Placebo. His Primary biliary cirrhosis and Hepatology study, which is part of a larger body of work in Gastroenterology, is frequently linked to In patient, bridging the gap between disciplines.
His biological study spans a wide range of topics, including Inflammatory bowel disease, Autoimmune pancreatitis, Liver disease, Proportional hazards model and Hazard ratio. His Cholestasis study incorporates themes from Cholestasis of pregnancy, Progressive familial intrahepatic cholestasis, Biliary cirrhosis, Obeticholic acid and Disease. The concepts of his Endocrinology study are interwoven with issues in Messenger RNA and Hepatocyte.
His primary areas of investigation include Internal medicine, Gastroenterology, Primary sclerosing cholangitis, Liver transplantation and Cholestasis. His Endocrinology research extends to the thematically linked field of Internal medicine. His Gastroenterology research is multidisciplinary, relying on both Biomarker, Placebo and Surgery.
His Primary sclerosing cholangitis research incorporates elements of Inflammatory bowel disease, Autoimmune pancreatitis, Proportional hazards model, Hazard ratio and Bile duct. His research integrates issues of Autoimmune hepatitis and Primary biliary cirrhosis in his study of Liver transplantation. His work deals with themes such as Cirrhosis and Obeticholic acid, which intersect with Ursodeoxycholic acid.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
Ulrich Beuers;Kirsten M. Boberg;Roger W. Chapman;Olivier Chazouillères.
Journal of Hepatology (2009)
Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited
Gustav Paumgartner;Ulrich Beuers.
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu;Vlad Ratziu;Stephen A. Harrison;Sven Francque;Pierre Bedossa.
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis
F. Nevens;P. Andreone;G. Mazzella;S. I. Strasser.
The New England Journal of Medicine (2016)
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
Gideon M. Hirschfield;Ulrich Beuers;Christophe Corpechot;Pietro Invernizzi.
Journal of Hepatology (2017)
Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review
Kirsten Boonstra;Ulrich Beuers;Cyriel Y. Ponsioen.
Journal of Hepatology (2012)
Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
Nature Clinical Practice Gastroenterology & Hepatology (2006)
Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.
Kirsten Boonstra;Rinse K. Weersma;Karel J. van Erpecum;Erik A. Rauws.
Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus
Andreas E. Kremer;Job J.W.W. Martens;Wim Kulik;Franziska Ruëff.
New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond
Ulrich Beuers;Michael Trauner;Peter Jansen;Raoul Poupon.
Journal of Hepatology (2015)
Journal of Hepatology
(Impact Factor: 30.083)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: